Compare SPDR Gold Trust (GLD) vs 10X Genomics Inc (TXG) Price & Performance

GLD is trading at $375.88, down 1.66% over the past 24 hours amid broader market pressure from rising Treasury yields and Federal Reserve policy uncertainty. The technical picture remains bearish with moving averages and oscillators signaling continued downward momentum, while key support levels cluster around $372-375. Recent news highlights gold's struggle to maintain gains despite weak economic data, with prices testing critical support zones.

The outlook for GLD remains challenged by persistent headwinds from elevated yields and dollar strength, though some analysts see tactical buying opportunities at current levels. Key risks include further Fed tightening and deteriorating technical momentum, while potential catalysts include sustained inflation concerns and geopolitical tensions that could revive safe-haven demand.

10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.

TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.